Fig. 1
From: Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
SAHA inhibits clonogenic growth of human breast cancer cells. (A) MCF7, (B) MDA-MB-231, and (C) MDA-MB-435 cells were treated with suberoylanilide hydroxamic acid (SAHA) at concentrations ranging from 0.1 to 4 µM for 2–3 weeks, and then analyzed for cell survival by colony formation assays. The bars represent standard deviations of three independent experiments.